Samuel H Zwillich
Overview
Explore the profile of Samuel H Zwillich including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
3428
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hauber B, Whichello C, Mauer J, Law E, Trapali M, Whalen E, et al.
J Dermatol
. 2025 Jan;
52(3):510-514.
PMID: 39812238
Ritlecitinib is an oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma (JAK3/TEC) family kinase inhibitor approved for the treatment of severe alopecia areata (AA). Benefit-risk profiles of two doses...
2.
Piliang M, Lynde C, King B, Mirmirani P, Sinclair R, Senna M, et al.
J Am Acad Dermatol
. 2024 Oct;
92(2):276-284.
PMID: 39423930
Background: Few treatments for alopecia areata have demonstrated sustained efficacy. Objective: Evaluate the efficacy and safety of continued ritlecitinib treatment to week 48 in patients with alopecia areata with or...
3.
Anderson S, Cavaletti G, Hood L, Polydefkis M, Herrmann D, Rance G, et al.
Pharmacol Res Perspect
. 2024 Jul;
12(4):e1204.
PMID: 38969959
Reversible axonal swelling and brainstem auditory evoked potential (BAEP) changes were observed in standard chronic (9-month) toxicology studies in dogs treated with ritlecitinib, an oral Janus kinase 3/tyrosine kinase expressed...
4.
Sinclair R, Law E, Zhang X, Zhang F, Napatalung L, Zwillich S, et al.
Dermatology
. 2024 Jun;
240(5-6):767-777.
PMID: 38934147
Introduction: Patients with alopecia areata (AA) report high levels of dissatisfaction with commonly used treatments. Patient-reported outcomes are essential to understanding patients' experiences with AA treatments. The objective of this...
5.
Tanaka Y, Takeuchi T, Valdez H, Collinge M, Zwillich S, Toyoizumi S, et al.
Mod Rheumatol
. 2024 May;
34(6):1115-1124.
PMID: 38801704
Objectives: We characterised changes in absolute lymphocyte counts (ALCs) and lymphocyte subset counts (LSCs), and their relationship to incidence of serious infection events (SIEs) and herpes zoster (HZ) events in...
6.
King B, Soung J, Tziotzios C, Rudnicka L, Joly P, Gooderham M, et al.
Am J Clin Dermatol
. 2024 May;
25(4):689.
PMID: 38789821
No abstract available.
7.
Sorensen S, George P, Jagun O, Wolk R, Napatalung L, Zwillich S, et al.
Dermatol Ther (Heidelb)
. 2024 Apr;
14(4):993-1006.
PMID: 38625633
Introduction: Alopecia areata (AA) is an autoimmune skin disease presenting as nonscarring hair loss. Information on the epidemiology of AA, especially the occurrence of AA and its subtypes within the...
8.
King B, Soung J, Tziotzios C, Rudnicka L, Joly P, Gooderham M, et al.
Am J Clin Dermatol
. 2024 Jan;
25(2):299-314.
PMID: 38263353
Background: The ALLEGRO phase 2a and 2b/3 studies demonstrated that ritlecitinib, an oral JAK3/TEC family kinase inhibitor, is efficacious at doses of ≥ 30 mg in patients aged ≥ 12...
9.
Martin D, Telliez J, Pleasic-Williams S, Zhang Y, Tierney B, Blatnik M, et al.
J Clin Pharmacol
. 2023 Sep;
64(1):67-79.
PMID: 37691236
Ritlecitinib is a small molecule in clinical development that covalently and irreversibly inhibits Janus kinase 3 (JAK3) and the TEC family of kinases (BTK, BMX, ITK, TXK, and TEC). This...
10.
Hordinsky M, Hebert A, Gooderham M, Kwon O, Murashkin N, Fang H, et al.
Pediatr Dermatol
. 2023 Jul;
40(6):1003-1009.
PMID: 37455588
Background/objectives: This subgroup analysis of the ALLEGRO phase 2b/3 trial (NCT03732807) evaluated the efficacy and safety of ritlecitinib, an oral, selective dual JAK3/TEC family kinase inhibitor, for the treatment of...